Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 01:50PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

HAEMATOLOGY

GLYCOSYLATED HAEMOGLOBIN (HBA1C)

GLYCOSYLATED HAEMOGLOBIN (HbA1c):	**7 H**	**%**	**4.0 - 6.4**
WHOLE BLOOD			
by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)			
ESTIMATED AVERAGE PLASMA GLUCOSE	**154.2 H**	**mg/dL**	**60.00 - 140.00**
by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)			

INTERPRETATION:

AS PER AMERICAN DIABETES ASSOCIATION (ADA):		
REFERENCE GROUP	**GLYCOSYLATED HEMOGLOGIB (HBAIC) in %**	
Non diabetic Adults >= 18 years	<5.7	
At Risk (Prediabetes)	5.7 – 6.4	
Diagnosing Diabetes	>= 6.5	
Therapeutic goals for glycemic control	**Age > 19 Years**	
	Goals of Therapy:	< 7.0
	Actions Suggested:	>8.0
	Age < 19 Years	
	Goal of therapy:	<7.5

COMMENTS:

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.

2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAIc. Converse is true for a diabetic previously under good control but now poorly controlled.

3.Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropiate.

4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications

5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution , given the pathological processes including anemia,increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 01:50PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

LIFOTRONIC Graph Report

Name :	Case :	Patient Type :	Test Date : 06/08/2024 13:33:14	
Age :	Department :	Sample Type : Whole Blood EDTA	Sample Id : 01514553	
Gender :			Total Area : 14496	

Peak Name	Retention Time(s)	Absorbance	Area	Result (Area %)
HbA0	69	4312	12735	86.2
HbA1c	38	96	1031	7.0
La1c	25	51	367	2.5
HbF	19	15	17	0.1
Hba1b	13	65	223	1.5
Hba1a	11	34	123	0.8



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 11:26AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

CLINICAL CHEMISTRY/BIOCHEMISTRY

GLUCOSE FASTING (F)

GLUCOSE FASTING (F): PLASMA *by GLUCOSE OXIDASE - PEROXIDASE (GOD-POD)*	**119.78^{H}**	**mg/dL**	**NORMAL: < 100.0** **PREDIABETIC: 100.0 - 125.0** **DIABETIC: > 0R = 126.0**

INTERPRETATION

IN ACCORDANCE WITH AMERICAN DIABETES ASSOCIATION GUIDELINES:

1. A fasting plasma glucose level below 100 mg/dl is considered normal.
2. A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood test (after consumption of 75 gms of glucose) is recommended for all such patients.
3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Mr. AJAY BAWEJA**		
AGE / GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 11:37AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
	LIPID PROFILE : BASIC		
CHOLESTEROL TOTAL: SERUM *by CHOLESTEROL OXIDASE PAP*	115.87	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: SERUM *by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)*	116.27	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROL (DIRECT): SERUM *by SELECTIVE INHIBITION*	31.63	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROL: SERUM *by CALCULATED, SPECTROPHOTOMETRY*	60.99	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLESTEROL: SERUM *by CALCULATED, SPECTROPHOTOMETRY*	84.24	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTEROL: SERUM *by CALCULATED, SPECTROPHOTOMETRY*	23.25	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERUM ***by CALCULATED, SPECTROPHOTOMETRY***	**348.01 L**	**mg/dL**	**350.00 - 700.00**
CHOLESTEROL/HDL RATIO: SERUM *by CALCULATED, SPECTROPHOTOMETRY*	3.66	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0
LDL/HDL RATIO: SERUM *by CALCULATED, SPECTROPHOTOMETRY*	1.93	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 11:37AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
TRIGLYCERIDES/HDL RATIO: SERUM *by CALCULATED, SPECTROPHOTOMETRY*	3.68	RATIO	3.00 - 5.00

INTERPRETATION:

1.Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL , VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.
5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 11:37AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
CREATININE			
CREATININE: SERUM *by ENZYMATIC, SPECTROPHOTOMETRY*	1.15	mg/dL	0.40 - 1.40

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 11:00AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
ENDOCRINOLOGY			
THYROXINE (T4)			
THYROXINE (T4): SERUM *by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)*	10.53	µgm/dL	4.87 - 12.60

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 11:00AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

THYROID STIMULATING HORMONE (TSH)

THYROID STIMULATING HORMONE (TSH): SERUM *by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)* 3rd GENERATION, ULTRASENSITIVE	**0.288**[L]	**µIU/mL**	**0.35 - 5.50**

INTERPRETATION:

AGE	REFFERENCE RANGE (µIU/mL)
0 – 5 DAYS	0.70 – 15.20
6 Days – 2 Months	0.70 – 11.00
3 – 11 Months	0.70 – 8.40
1 – 5 Years	0.70 – 7.00
6 – 10 Years	0.60 – 5.50
11 - 15	0.50 – 5.50
> 20 Years (Adults)	0.27 – 5.50
PREGNANCY	
1st Trimester	0.10 - 3.00
2nd Trimester	0.20 - 3.00
3rd Trimester	0.30 - 4.10

NOTE:-*TSH levels are subjected to circardian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50 %. Hence time of the day has influence on the measured serum TSH concentration.*

USE:- TSH controls biosynthesis and release of thyroid harmones T4 & T3. It is a sensitive measure of thyroid function, especially useful in early or subclinical hypothyroidism, before the patient develops any clinical findings or goitre or any other thyroid function abnormality.

INCREASED LEVELS:

1.Primary or untreated hypothyroidism, may vary from 3 times to more than 100 times normal depending on degree of hypofunction.
2.Hypothyroid patients receiving insufficient thyroid replacement therapy.
3.Hashimotos thyroiditis.
4.DRUGS: Amphetamines, Iodine containing agents and dopamine antagonist.
5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge.

DECREASED LEVELS:

1.Toxic multi-nodular goitre & Thyroiditis.
2.Over replacement of thyroid harmone in treatment of hypothyroidism.
3.Autonomously functioning Thyroid adenoma
4.Secondary pituatary or hypothalmic hypothyroidism
5.Acute psychiatric illness
6.Severe dehydration.
7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.
8.Pregnancy: 1st and 2nd Trimester

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 11:00AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

LIMITATIONS:

1.TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy.
2.Autoimmune disorders may produce spurious results.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 01:01PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

INSULIN FASTING (F)

INSULIN FASTING (F)	12.6	µIU/ml	2.0 - 25.0

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

INTERPRETATION:-

1.Insulin is a hormone produced by the beta cells of the pancreas. It regulates the uptake and utilization of glucose and is also involved in protein synthesis and triglyceride storage.
2.Type 1 diabets (insulin-dependent diabetes) is caused by insulin deficiency due to destruction of insulin producing pancreatic islets (beta) cells.
3.Type 2 diabetes (noninsulin dependent diabetes) is characterized by resistance to the action of insulin (insulin resistance).
4.The test is useful for management of diabetes mellitus and for diagnoses of insulinomas, when used in conjunction with proinsulin and C-peptide measurements.

NOTE:

1.No standard referance range has yet been established for INSULIN POST-PRANDIAL (PP) in indian population, therefore same could not be provided along with test. However various studies done on several populations mention that the range of INSULIN PP can vary somewhere from 5-79 mIU/L which can be used for clinical purpose.

2.This assay has 100% cross-reactivity with recombinant human insulin (Novolin R and Novolin N). It does not recognize other commonly used analogues of injectable insulin (ie, insulin lispro, insulin aspart, and insulin glargine).

INTERPRETATIVE GUIDE:

1.During prolonged fasting, when the patient's glucose level is reduced to <40 mg/dL, elevated insulin level plus elevated levels of proinsulin and C-peptide suggest insulinomaS.
2.Insulin levels generally decline in patients with type 1 diabetes mellitus.
3.In the early stage of type 2 diabetes, insulin levels are either normal or elevated. In the late stage of type 2 diabetes, insulin levels decline.
4.In normal individuals, insulin levels parallel blood glucose levels.
5.Patients on insulin therapy may develop anti-insulin antibodies. These antibodies may interfere in the assay system, causing inaccurate results. In such individuals, measurement of free insulin FINS / Insulin, Free, Serum should be performed.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 01:32PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

C-PEPTIDE

C-PEPTIDE: SERUM *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	**4.63^{H}**	**ng/mL**	**0.30 - 3.80**

INTERPRETATION:-

C-peptde is useful in distinguishing insulinomas from exogenous insulin administration. When insulin secretion is diminished, as in insulin dependent diabetes, low c-peptide levels are to be expected. Elevated c-peptide levels may result from increased beta cell activity associated with insulinomas. C-Peptide is also useful in monitoring patients who have received islet cell or pancreatic transplants.

C-peptide orginates in pancreatic beta cells as an inert byproduct in the synthesis of insulin from proinsulin. Insulin and c-peptide are released from proinsulin in equimolar concentration into the circulation. C-peptide levels can therefore serve as an index of insulin secretion. Anti-insulin antibodies are commonly found in patients who have underfore insulin therepy. These antibodies may interfere with insulin assay. C-peptide measurments are therefore used as an alternative measurment index in this context.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Mr. AJAY BAWEJA**		
AGE/ GENDER	: 54 YRS/MALE	**PATIENT ID**	: 1572062
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408060005**
REFERRED BY	:	**REGISTRATION DATE**	: 06/Aug/2024 07:42 AM
BARCODE NO.	: 01514553	**COLLECTION DATE**	: 06/Aug/2024 07:48AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 06/Aug/2024 02:35PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

CLINICAL PATHOLOGY

MICROALBUMIN/CREATININE RATIO - RANDOM URINE

MICROALBUMIN: RANDOM URINE *by SPECTROPHOTOMETRY*	12.59	mg/L	0 - 25
CREATININE: RANDOM URINE *by SPECTROPHOTOMETRY*	111.08	mg/dL	20 - 320
MICROALBUMIN/CREATININE RATIO - RANDOM URINE *by SPECTROPHOTOMETRY*	11.33	mg/g	0 - 30

***INTERPRETATION*:-**

PHYSIOLOGICALLY NORMAL:	mg/L	0 - 30
MICROALBUMINURIA:	mg/L	30 - 300
GROSS PROTEINURIA:	mg/L	> 300

Long standing un-treated Diabetes and Hypertension can lead to renal dysfunction.
2. Diabetic nephropathy or kidney disease is the most common cause of end stage renal disease(ERSD) or kidney failure.
3. Presence of Microalbuminuria is an early indicator of onset of compromised renal function in these patients.
4.Microalbuminuria is the condition when urinary albumin excre tion is between 30-300 mg & above this it is called as macroalbuminuria, the presence of which indicates serious kidney disease.
5.Microalbuminuria is not only associated with kidney disease but of cardiovascular disease in patients with dibetes & hypertension.
6.Microalbuminuria reflects vascular damage & appear to be a marker of of early arterial disease & endothelial dysfunction.
NOTE:- *IF A PATIENT HAS = 1+ PROTEINURIA (30 mg/dl OR 300 mg/L) BY URINE DIPSTICK (URINEANALYSIS), OVERT PROTEINURIA IS PRESENT AND TESTING FOR MICROALBUMIN IS INAPPROPIATE. IN SUCH A CASE, URINE PROTEIN:CREATININE RATIO OR 24 HOURS TOTAL URINE MICROPROTEIN IS APPROPIATE.*

*** End Of Report ***

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)